October 16, 2025
Trading, get it right or maybe wrong; does a hold fulfill a reward in this period with significant intraday swings
As I have written, “when dramatic upsides occur, investors are often unsure exactly what to do, but they frequently act as if they do know the best path forward – don’t be LULLED into an uncertainty position!”
Sector Q3 earnings begin with IQV Holdings (IQV) on 10/28, MiMedx (MDXG) Ionis Pharmaceuticals IONS), AxoGen AXGN) on 10/29 with Moderna (MRNA) on 11/6
Pre-open Signals: 4 Positive and 3 Negative Indications
If you understand the possibilities, the inevitable is easier to maneuver
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
October 15, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume
Challenging and questionable "aspects" state the obvious – a Ponzi Scheme!
They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing?
Accumulated deficit to date= $103.2 M in 12 years
WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ???
U.S. investors BEWARE, forewarned is forearmed?
October 16, 2025
I can’t seem to let go of this quote, “It’s always darkest before the pitch dark”
The VIX is again on the move, closing Thursday at 25.12, Wednesday at 20.41, Tuesday’s 20.36 following Monday’s 19.05 as shutdown proceeds to 16 days
Me, no Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you anyway? Technological advances and the increasing availability of data have made intel both available and complex. I see myself as a collector and my responsibility is to further educate and lead investors to interpreted data as I bridge the gap to an investment decision.
Never leave an investor uninformed!
October 15, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume Challenging and questionable "aspects" state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M in 12 years WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
October 12, 2025
In 2020, they looked and now in 2025, vaccines will become a core business. Reuters reported “The move marks a significant shift for the Japanese drugmaker, which had spent years trying to build a presence in cell therapy, particularly in cancer treatment.” TAK will focus on small molecule drugs, biologics and antibody-drug conjugates – areas it believes can deliver innovative medicines to patients more quickly and at greater scale. Takeda's current 5 core businesses are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies
September 29, 2025
For gross proceeds of $345 M QURE closed up +$5.09 or +9.37% to $59.40 with an aftermarket pricing of -$1.25 or -2.10% to $58.15 QURE had soared by 291% week-on-week to climb to a new all-time high based on astronomical performance of its delivered gene therapy treatment AMT-130 for Huntington’s disease.
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
